Healthy Clinical Trial
Official title:
Studying the Role of Brain Molecules for Decision Making
Verified date | May 2024 |
Source | University of Zurich |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of the present project is to elucidate the neuropharmacological mechanisms underlying value (choice preference) and attention (choice randomness) processing in humans. More specifically, the investigators test whether dopaminergic, noradrenergic and cholinergic interventions affect neural and behavioral processing of valuation and attention during decision-making. The investigators do this by up-regulating dopaminergic, noradrenergic or cholinergic neurotransmission pharmacologically through administration of methylphenidate, reboxetine, or nicotine. We test the hypothesis that methylphenidate, reboxetine, or nicotine reduce choice randomness and that this effect is underpinned by an effect on attention and/or value processing.
Status | Completed |
Enrollment | 160 |
Est. completion date | December 13, 2021 |
Est. primary completion date | December 13, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 35 Years |
Eligibility | Inclusion Criteria: - Physically and psychiatrically healthy (as defined by exclusion criteria) men and women aged 18-35 years - Ability and willingness to participate in the study - Willingness to not eat or drink any food/beverage containing caffeine or alcohol 12 hours prior to the administration of study medication (asked in screening session) - Willingness to not eat or drink grapefruit or grapefruit related citrus fruits (e.g., Seville oranges, pomelos) from 7 days prior to the administration of study medication (asked in screening session) - Good command of English language (be able to understand the task instructions and in the unlikely case of adverse effects inform the examiner) - Signed informed consent Exclusion Criteria: - Serious past brain disease or injury - Frequent headaches (of any sort, > 1/week) or migraine (irrespective of frequency) - History of epileptic seizures - Any neurological disorder - Surgery to head or heart (MRI safety, potential metal pieces) - Pacemaker, hearing aid or neurostimulator (MRI safety, metal pieces) - Known cardiac or cardiovascular disease or anomaly - Family history of sudden death due to cardiac arrhythmia - High or low blood pressure, history of heart attack, infrequent heartbeat - Respiratory problems (including difficulty with breathing through the nose) - Glaucoma (present or past) - Insufficiency of kidney or liver, acute liver disease - Any psychiatric disorder (especially depression, mania, schizophrenia, addiction panic and suicidality) - Severe vocal or motor tics (methylphenidate, data quality) - Severe psychosomatic disorder (somatic complaints without clear medical cause, has a mental component) - Potential metal parts in body (MRI safety; metal splinters, gun wounds, shrapnel or surgical clips) - Pregnancy, nursing, or currently planned pregnancy - Allergy to drugs, particularly methylphenidate, reboxetine or nicotine - Severe intolerance to lactose including strong diarrhea after only a few mg (weak lactose intolerance is no exclusion criterion as medication only contains a very small dose (around 4 mg) of lactose) - Oversensitivity to hot pepper sauce (e.g., tabasco) - Currently taking any medication or recently participated in other clinical trials that might interfere with Methylphenidate and Reboxetine, especially MAO-Inhibitors (e.g. Aurorix (Moclobemid) and Azilect (Rasagilin), antipsychotics, antibiotics, and medication for heart diseases - Currently taking any further medication (besides birth control) or natural products (infrequent intake of natural products and/or food supplements need to be mentioned to the examiner) - Drug abuse (exclude people with a positive test) - Serious acute or chronic disease that could interfere with participation in the experiments - Inability to lie still in the scanner (e.g. due to itching, sneezing, coughing, claustrophobia) - Inability to understand the instructions - Participants with BMI < 18 - Clinically relevant score in STAI T (anxiety), measured during screening on a separate day - ECG demonstrating QTcF >450 msec or a QRS interval >120 msec at screening. If QTcF exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated two more times and the average of the three QTcF/QRS values should be used to determine participant eligibility, measured during screening on a separate day - Participants who eat or drink grapefruit or grapefruit related citrus fruits (e.g., Seville oranges, pomelos) or drinks from 7 days prior to the administration of study medication. - Participants who eat or drink any food/beverage containing caffeine or alcohol 12 hours before the study - Current smokers/tobacco consumers (exclude people whose cotinine level is higher than 50ng/ml with a urine test) - Phenylketonuria - Dental or jaw condition prohibiting gum chewing - Pheochromocytoma - Thyroid disorders - Diabetes - Type of angina where chest pain occurs at rest - Unpredictable severe constricting chest pain - Prickling or tingling of fingers and toes - Buerger's Disease - Throat irritation - Peptic ulcers - Esophagitis |
Country | Name | City | State |
---|---|---|---|
Switzerland | University of Zurich | Zurich |
Lead Sponsor | Collaborator |
---|---|
University of Zurich |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Computational parameters estimated from experimental data | Computational parameters are estimated from the data of participants during the decision-making tasks. Specifically, mathematical models will be applied to above-mentioned choice data and/or response time data. The estimated parameters reflect choice preference and stochasticity and are complementary to the descriptive measurements mentioned above. For example, utility functions will be estimated and the choice preferences are described by the concavititvity of utility functions. | All participants perform decision-making tasks after drug/placebo administration in the main experimental session lasting about 1 hour. | |
Primary | Choice data | Choice data made by participants are measured from the experimental tasks. More specifically, the investigators calculate choice preferences, such as the percentage of trials in which participants chose options with probabilistic outcomes in the RISKGARP task and the bids they made in the Range-WTP task, the percentage of exploitative/explorative choices in the four-armed bandit task, and the leaving time in the foraging task. Moreover, the investigators determine choice sub-optimality, such as the number of choices violating transitivity in the RISKGARP task, the inconsistency of bids in repeated trials in the Range-WTP task, the percentage of selecting the worst option in the four-armed bandit task, and the difference between optimal leaving time and actual leaving time in the foraging task. | All participants perform decision-making tasks after drug/placebo administration in the main experimental session lasting about 1 hour. | |
Primary | Response time data | Response times are measured from experimental tasks. The investigators calculate how long participants take to make decisions in each trial. | All participants perform decision-making tasks after drug/placebo administration in the main experimental session lasting about 1 hour. | |
Secondary | The size of pupil dilation | Pupil size is measured using eye-tracker while participants perform the experimental tasks. Baseline pupil size is also measured before the drug/placebo administration. | Pupil size is measured in the main experimental session before drug/placebo administration and through study completion lasting about 1 hour. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |